Generated by AI
Seer, Inc. Class A Common Stock represents ownership in Seer, a life sciences company focused on proteomics. Seer develops and commercializes the Proteograph Product Suite, an integrated platform that combines proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to support high-throughput protein analysis. Its products are designed for research use in academic institutions, biotechnology and biopharmaceutical companies, and other scientific laboratories seeking deeper, more unbiased insights into biological samples. By enabling protein profiling at scale, Seer plays a specialized role in the broader tools-and-services segment of the life sciences market, where proteomic technologies support biomarker discovery, drug research, and translational science. The company is headquartered in Redwood City, California.
Website3800 Bridge Parkway
Redwood City, CA, 94065
United States
The latest articles about SEER.
REDWOOD CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the third quarter 2026 on Tuesday, November 10, 2026. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archi
Summary of Jul 6's posts. Generated by AI.
No summary yet.
Summary of Jul 6's posts. Generated by AI.
Summary of Mar 3's posts. Generated by AI.
No summary yet.
Summary of Mar 3's posts. Generated by AI.
Investors talking about SEER also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.